摘要
目的:探讨罗格列酮对2型糖尿病患者骨密度(BMD)及骨代谢指标的影响。方法:172例2型糖尿病患者随机分为对照组和罗格列酮治疗组,每组86例。罗格列酮治疗组给予罗格列酮4mg.d-1,治疗3个月。分别于治疗前后,测定2组的BMD、血清骨碱性磷酸酶(BAP)、骨钙素(OC)和护骨素(OPG)等指标的变化。结果:治疗3个月后,罗格列酮治疗组髋部及腰椎BMD显著下降,血清BAP、OC和OPG也明显降低;而对照组的BMD、血清BAP、OC和OPG在治疗前后无明显变化。结论:罗格列酮可能通过降低血清BAP、OC和OPG水平,使2型糖尿病患者的BMD降低,从而具有潜在的致骨质疏松的作用。
OBJECTIVE To investigate the effects of rosiglitazone on bone mineral density and bone metabolism indexes in patients with type 2 diabetes. METHODS 172 patients with type 2 diabetes were randomly divided into control group and rosiglitazone treated group (86 patients in each group). The patients in rosiglitazone treated group were treated with rosiglitazone (4 mg·d ^-1 ) for 3 months. Then bone mineral density, serum bone-specific alkaline phosphatase, osteocalcin and osteoprotegerin were detected in the two groups before and after treatment. RESULTS After treatment for 3 months, decreased levels of hip and lumbar spine BMD, serum bone-specie alkaline phosphatase, osteoealein and osteoprotegerin were found in rosiglitazone treating group. However. there were no significant differences in the level of bone mineral density, serum bone-specie alkaline phosphatase, osteocalcin and osteoprotegerin between before and after treatment among the control group. CONCLUSION Rosiglitazone decreases bone mineral density among patients with type 2 diabetes via reducing the levels of serum bone-specific alkaline phosphatase, osteocalcin and osteoprotegerin,then may leads to osteoporosis.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2011年第7期577-579,共3页
Chinese Journal of Hospital Pharmacy
关键词
罗格列酮
2型糖尿病
骨密度
碱性磷酸酶
骨钙素
护骨素
rosiglitazone
type 2 diabetes
bone mineral density
bonespecific alkaline phosphalase
osteocalcin
osteoprotegerin